VANCOUVER, Aug. 15 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing additional diameters of its Quill(TM) Self-Retaining System (SRS) Polydioxanone (PDO) product line.
The Quill(TM) SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures. Angiotech is now able to offer a broad range of PDO suture products with diameters ranging from sizes 2 to 4-0.
"We are pleased to be able to market these new diameters of PDO sutures. As we have indicated, we intend to continue to expand the Quill(TM) SRS product line to cover multiple procedures for wound closure and tissue approximation," added Dr. Hunter.
Angiotech plans to exhibit the Quill(TM) SRS product line at the Annual Meeting of the American Society of Plastic Surgeons (ASPS) to be held on October 26-31, 2007 in Baltimore, MD.
About the Quill(TM) Self-Retaining System (SRS)
The innovative Quill(TM) SRS represents the next generation of wound closure technology. A patented helical barbed design enables surgeons to suture without the use of knots. The absence of knots provides a wide range of clinical and economic benefits, including:
Potential to improve patient outcomes:
- Minimizes complications associated with knots
- Potential to improve wound healing
- May enhance cosmesis
Potential to save time in the operating room:
- Achieves potentially significant time savings, especially in suture
Enhanced procedural te
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.